The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06050-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2024. Verfasst von Shan Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Nucleophosmin, Sulfonamides. Die Arbeit nennt 125 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, China.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is the most prevalent hematologic malignancy in adults. In 2022, the European LeukemiaNet (ELN) has updated its prognostic system that incorporates cytogenetics and molecular genetics based on data from patients undergoing intensive chemotherapy (IC). Recently, a risk stratification framework has been established for hypomethylating agents (HMA)-based low-intensity treatment (LIT) to fill the gaps in stratification for this treatment modality, but this needs further refinement. Venetoclax (VEN), a BH3 mimetic, targets BCL-2 to modulate apoptosis and metabolism in AML cells. Its combination with HMA or low-dose cytarabine (LDAC) has been shown to enhance the response rates and prolong the survival outcomes of older or unfit patients with AML. In this review, we delved into the prognostic significance of FLT3-ITD and IDH mutations when used in combination with VEN and HMA, as well as in conjunction with their specific inhibitors. We also explored the role of VEN in NPM1-mutated AML and its efficacy in splicing factor mutations AML. Additionally, we examined the response rates and survival outcomes of CBF-AML when treated with a VEN-based regimen. Moving forward, it is imperative that risk stratification for LIT becomes more nuanced to better align with the requirements of personalized diagnosis and treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China.
- Department of Hematology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China.
- Hangzhou Institute of Medicine (HlM), Chinese Academy of Sciences, Hangzhou, 310022, China.
- Department of Hematology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China. yamintan2023@163.com.
- Hangzhou Institute of Medicine (HlM), Chinese Academy of Sciences, Hangzhou, 310022, China. yamintan2023@163.com.
Förderung
- Natural Science Foundation of Zhejiang Province, China
Zitieren
APA
Zheng, S., Tong, Y., Yang, L., Chen, J., & Tan, Y. (2024). The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment. Annals of Hematology. https://doi.org/10.1007/s00277-024-06050-x
Vancouver
Zheng S, Tong Y, Yang L, Chen J, Tan Y. The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment. Annals of Hematology. 2024. doi:10.1007/s00277-024-06050-x
BibTeX
@article{Zheng2024,
author = {Zheng, Shan and Tong, Yuxin and Yang, Linlin and Chen, Jiayi and Tan, Yamin},
title = {The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06050-x}
}
EUVIMED